These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36969845)

  • 1. Early and sustained improvements of lung clearance index from two to sixteen weeks of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis-a real world study.
    Appelt D; Steinkamp G; Sieber S; Ellemunter H
    Front Pharmacol; 2023; 14():1125853. PubMed ID: 36969845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
    Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for
    Mall MA; Brugha R; Gartner S; Legg J; Moeller A; Mondejar-Lopez P; Prais D; Pressler T; Ratjen F; Reix P; Robinson PD; Selvadurai H; Stehling F; Ahluwalia N; Arteaga-Solis E; Bruinsma BG; Jennings M; Moskowitz SM; Noel S; Tian S; Weinstock TG; Wu P; Wainwright CE; Davies JC
    Am J Respir Crit Care Med; 2022 Dec; 206(11):1361-1369. PubMed ID: 35816621
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.
    Bower JK; Volkova N; Ahluwalia N; Sahota G; Xuan F; Chin A; Weinstock TG; Ostrenga J; Elbert A
    J Cyst Fibros; 2023 Jul; 22(4):730-737. PubMed ID: 36963986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
    Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.
    Schechter MS; Sabater-Anaya N; Oster G; Weycker D; Wu H; Arteaga-Solis E; Bagal S; McGarry LJ; Van Brunt K; Geiger JM
    Pulm Ther; 2023 Dec; 9(4):479-498. PubMed ID: 37874528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.
    Olivier M; Kavvalou A; Welsner M; Hirtz R; Straßburg S; Sutharsan S; Stehling F; Steindor M
    Front Pharmacol; 2023; 14():1176815. PubMed ID: 37229253
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.
    Streibel C; Willers CC; Pusterla O; Bauman G; Stranzinger E; Brabandt B; Bieri O; Curdy M; Bullo M; Frauchiger BS; Korten I; Krüger L; Casaulta C; Ratjen F; Latzin P; Kieninger E
    J Cyst Fibros; 2023 Jul; 22(4):615-622. PubMed ID: 36635199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One
    Zemanick ET; Taylor-Cousar JL; Davies J; Gibson RL; Mall MA; McKone EF; McNally P; Ramsey BW; Rayment JH; Rowe SM; Tullis E; Ahluwalia N; Chu C; Ho T; Moskowitz SM; Noel S; Tian S; Waltz D; Weinstock TG; Xuan F; Wainwright CE; McColley SA
    Am J Respir Crit Care Med; 2021 Jun; 203(12):1522-1532. PubMed ID: 33734030
    [No Abstract]   [Full Text] [Related]  

  • 10. Real world outcomes of CFTR modulator therapy in Australian adults and children.
    Kuek S; McCullagh A; Paul E; Armstrong D
    Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one
    Daines CL; Tullis E; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Rowe SM; Selvadurai H; Taylor-Cousar JL; Withers NJ; Ahluwalia N; Moskowitz SM; Prieto-Centurion V; Tan YV; Tian S; Weinstock T; Xuan F; Zhang Y; Ramsey B; Griese M;
    Eur Respir J; 2023 Dec; 62(6):. PubMed ID: 37945033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis.
    Keens T; Hoffman V; Topuria I; Elder K; Cerf S; Mulder K; Roberts J; Lysinger J; Del Carmen Reyes M; Berdella M; Cairns AM; Jain M; Ganapathy V; Lou Y; Morcos B; Wu C; Sass L;
    Heliyon; 2024 Apr; 10(7):e28508. PubMed ID: 38586424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.
    Marshall LZ; Espinosa R; Starner CI; Gleason PP
    J Manag Care Spec Pharm; 2023 Jun; 29(6):599-606. PubMed ID: 37276039
    [No Abstract]   [Full Text] [Related]  

  • 14. Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.
    Tümmler B
    Front Pharmacol; 2023; 14():1158207. PubMed ID: 37025483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.
    Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L
    Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials.
    He R; Lin F; Deng Z; Yu B
    SAGE Open Med; 2024; 12():20503121231225874. PubMed ID: 38249954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-Ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    medRxiv; 2023 Nov; ():. PubMed ID: 37645804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?
    Niedermayr K; Gasser V; Rueckes-Nilges C; Appelt D; Eder J; Fuchs T; Naehrlich L; Ellemunter H
    Ther Adv Chronic Dis; 2022; 13():20406223221108627. PubMed ID: 35959505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.
    Stekolchik E; Saul D; Chidekel A
    Respir Med Case Rep; 2022; 40():101775. PubMed ID: 36411821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor.
    Gómez-Ganda L; Galván-Blasco P; Fernández-Polo A; Cardona V; García-Palop B; Parramón-Teixidó CJ; Polverino E; Álvarez-Fernández A
    Front Pharmacol; 2024; 15():1392986. PubMed ID: 38933680
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.